OverT Bio

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a partnership with US biotechnology company OverT Bio, Inc. to develop next-generation cell therapies targeting solid tumors. The collaboration will leverage Nona’s heavy-chain antibody (HCAb) Harbour Mice platform, with no financial specifics disclosed. Nona Bio’s HCAb…